Novartis reports positive Phase III results for remibrutinib in RMS

Novartis has reported that its oral BTK inhibitor, remibrutinib, met its primary endpoint in two Phase III trials for adults with relapsing MS. Nearly 2,000 patients in countries worldwide participated in the REMODEL-1 and REMODEL-2 studies. Both trials showed remibrutinib was superior across key secondary endpoints, including reductions in MRI lesions. Credit: New Africa / Shutterstock.com. Novartis has reported that its oral Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib, met its primary endpoint in two Phase III trials, REMODEL-1 and REMODEL-2, for adults with relapsing multiple sclerosis (RMS). In the multicentre, double-blind studies, remibrutinib showed a statistically significant reduction in annualised…

Source: Clinical Trials Arena